HIMS & HERS (HIMS) Q2 income 2025
The HERS app arranged on a smartphone in New York on February 12, 2025.
Gabby Jones | Bloomberg | Getty pictures
Shares of Hims & Hers Health On Monday, 9% fell back in the extended trade after the Telemealth Company had reported results in the second quarter that missed Wall Street sales expectations.
For example, the company worked on the average analyst estimates on the basis of the LSEG:
- Win each share: 17 cents are expected compared to 15 cents
- Revenue: $ 544.8 million expected compared to USD 552 million
After a press release, sales at HIMS & BE increased in the second quarter of US $ 315.6 million by 73%in the same period of the previous year. In the same period, HIMS & HER reported a net result of $ 42.5 million or 17 cents per share compared to $ 13.3 million or 6 cents per share.
For his third quarter, HIMS & HERS said that it would spend sales between $ 570 million and $ 590 million, while analysts expected $ 583 million. The company stated that its adjusted profit before interest, taxes, depreciation and amortization or EBITDA will be between $ 60 million and $ 70 million for the quarter. 77.1 million US dollars expected from Street Account.
Hims & Her has been controversial in the past few months due to the continued sale of composite GLP-1, which are cheaper versions of the blockbuster diabetes and weight loss medication. MONICATIONS MASS Production in brand treatments can be produced, but the US Food and Drug Administration announced in February that ongoing care problems have been solved.
Some telemedicine companies, including HIMS & Her, have continued to offer the composed medication. It is legal for patients to access personalized doses of the knockoffs in unique cases, e.g. HIMS & HER stated that consumers may continue to be able to access personalized cans via their website if they are clinically applicable.
In June, Hims & Hershares fell after a short-lived collaboration with more than 30% Novo Nordisk fell apart. The drugmaker said that Hims & Hins “could not adhere to the law that prohibits the creation of increased drugs” under the “wrong shape” of personalization.
For the second quarter, HIMS & HOR reported an adjusted EBITDA of $ 82 million, compared to $ 39.3 million in the previous year and the 73 million US dollar expected by Street Account.
Hims & Hin will align his quarterly call with investors at 5:00 p.m. (ET).
Do not miss these findings from CNBC Pro
Stock Diagram -iconstock -Igram -Symbol
YTD diagram by Hims & Huls Health.
– Annika Kim Constantino from CNBC contributed to this report.
